Novo Nordisk A/S (NVO)
46.94
+0.20
(+0.44%)
USD |
NYSE |
Aug 24, 16:00
47.05
+0.10
(+0.22%)
After-Hours: 20:00
Novo Nordisk Debt to Equity Ratio : 0.6333 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.6333 |
| March 31, 2026 | 0.7209 |
| December 31, 2025 | 0.6749 |
| September 30, 2025 | 0.5957 |
| June 30, 2025 | 0.5906 |
| March 31, 2025 | 0.857 |
| December 31, 2024 | 0.7164 |
| September 30, 2024 | 0.4727 |
| June 30, 2024 | 0.5071 |
| March 31, 2024 | 0.2722 |
| December 31, 2023 | 0.2534 |
| September 30, 2023 | 0.2854 |
| June 30, 2023 | 0.2841 |
| March 31, 2023 | 0.3195 |
| December 31, 2022 | 0.3088 |
| September 30, 2022 | 0.3387 |
| June 30, 2022 | 0.3416 |
| March 31, 2022 | 0.3829 |
| December 31, 2021 | 0.3766 |
| September 30, 2021 | 0.208 |
| June 30, 2021 | 0.2099 |
| March 31, 2021 | 0.1651 |
| December 31, 2020 | 0.1635 |
| September 30, 2020 | 0.0689 |
| June 30, 2020 | 0.069 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0756 |
| December 31, 2019 | 0.0778 |
| September 30, 2019 | 0.082 |
| June 30, 2019 | 0.0797 |
| March 31, 2019 | 0.0913 |
| December 31, 2018 | 0.0099 |
| September 30, 2018 | 0.0071 |
| June 30, 2018 | 0.005 |
| March 31, 2018 | 0.0052 |
| December 31, 2017 | 0.034 |
| September 30, 2017 | 0.0055 |
| June 30, 2017 | 0.0347 |
| March 31, 2017 | 0.0152 |
| December 31, 2016 | 0.0051 |
| September 30, 2016 | 0.011 |
| June 30, 2016 | 0.0095 |
| March 31, 2016 | 0.0109 |
| December 31, 2015 | 0.0228 |
| September 30, 2015 | 0.0146 |
| June 30, 2015 | 0.0188 |
| March 31, 2015 | 0.0185 |
| December 31, 2014 | 0.0179 |
| September 30, 2014 | 0.0075 |
| June 30, 2014 | 0.0111 |
| March 31, 2014 | 0.0239 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| AstraZeneca PLC | 0.7166 |
| Johnson & Johnson | 0.5771 |
| Eli Lilly & Co. | 1.621 |
| Merck & Co., Inc. | 1.286 |
| Novartis AG | 1.180 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 91.00B |
| Total Liabilities (Quarterly) | 57.15B |
| Shareholders Equity (Quarterly) | 33.84B |
| Current Ratio | 0.8729 |
| Net Debt Paydown Yield | -0.53% |